Hjem › Indolent multipelt myelom › Michigan
Indolent multipelt myelom kliniske forsøg i Michigan
4 studier for Indolent multipelt myelom søger deltagere på steder i Michigan.
Officiel studietekst (engelsk)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07393282Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- MyMichigan Medical Center Gratiot, Alma
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- og 42 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT03937635A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- University of Michigan Health, Ann Arbor
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 8. jul. 2026 · NCT06140524Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT02269592Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.